CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Open-market buy 10% owner bought 165,667 shares at $8.40 ($1,391,686)
- 4 Open-market buy 10% owner bought 248,749 shares at an average $8.46 ($2,103,912)
- 4 Open-market buy 10% owner bought 1,459,641 shares at an average $6.73 ($9,826,941)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 4,895 shares at $8.53 ($41,754)
- 4 Open-market sale President and CEO sold 12,529 shares at $8.53 ($106,872)
- 4 Open-market sale Chief Scientific Officer sold 3,756 shares at $8.53 ($32,039)
- 4 Open-market sale Chief Legal Officer sold 3,756 shares at $8.53 ($32,039)
- 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
Page 3 of 13 · 253 filings